Daiichi Sankyo is set to restructure its wholly-owned Kitasato Daiichi Sankyo Vaccine subsidiary into a specialised manufacturing division to enhance stable production and quality.
In August this year, Daiichi Sankyo will establish Daiichi Sankyo Biotech as a wholly owned subsidiary.
The change will be effective from 1 April next year, and all of the subsidiary’s functions, except manufacturing and production technologies and marketing approvals, will be shifted to Daiichi Sankyo.
The subsidary will be involved in contract manufacturing of vaccines, biologics and investigational drugs.
Kitasato Daiichi Sankyo Vaccine was founded in 2011 as a joint venture (JV) between Daiichi Sankyo and the Kitasato Institute.
The JV’s operations include research and development (R&D), production and the sale of vaccines to prevent and treat verioud infectious diseases in humans.
Kitasato Vaccine was created as a wholly owned subsidary in November last year during a review of its vaccine business structure.
After the integration, the division focussed on the quality and stable supply of vaccines, along with the R&D and commercialisation of new products.
Daiichi Sankyo is a research-based pharmaceutical company involved in making generic pharmaceuticals, vaccines and over-the-counter medicines.
With operations across the US, Japan and Europe, the company has various other subsidiaries, including Luitpold Pharmaceuticals, Plexxikon, Daiichi Sankyo Ilac Ticaret, Daiichi Sankyo UK and Daiichi Sankyo RD Novare.